The prognostic impact of Akt isoforms, PI3K and PTEN related to female steroid hormone receptors in soft tissue sarcomas

[1]  Sean E. Egan,et al.  Elevated PI3K signaling drives multiple Breast Cancer subtypes , 2011, Oncotarget.

[2]  T. Dønnem,et al.  Estrogen receptor and progesterone receptor are prognostic factors in soft tissue sarcomas. , 2011, International journal of oncology.

[3]  J. Meyerhardt,et al.  Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers , 2011, Cancer.

[4]  T. Dønnem,et al.  The Prognostic Impact of TGF-β1, Fascin, NF-κB and PKC-ζ Expression in Soft Tissue Sarcomas , 2011, PloS one.

[5]  G. Choi,et al.  Clinical significance of genetic variations in the PI3K/PTEN/AKT/mTOR pathway in Korean patients with colorectal cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Lara J. Monteiro,et al.  Constitutively Nuclear FOXO3a Localization Predicts Poor Survival and Promotes Akt Phosphorylation in Breast Cancer , 2010, PloS one.

[7]  G. Demetri,et al.  Soft tissue sarcoma. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

[8]  M. Sperl,et al.  Increasing incidence rates of soft tissue sarcomas? A population-based epidemiologic study and literature review. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  H. Nilsson‐Ehle,et al.  High immunohistochemical expression of p‐AKT predicts inferior survival in patients with diffuse large B‐cell lymphoma treated with immunochemotherapy , 2010, British journal of haematology.

[10]  J. Verweij,et al.  Future treatment of soft tissue sarcomas will be driven by histological subtype and molecular aberrations. , 2010, European journal of cancer.

[11]  L. Guillou,et al.  Soft tissue sarcomas with complex genomic profiles , 2010, Virchows Archiv.

[12]  Andrew H. Beck,et al.  Gene expression profiling for the investigation of soft tissue sarcoma pathogenesis and the identification of diagnostic, prognostic, and predictive biomarkers , 2010, Virchows Archiv.

[13]  T. Dønnem,et al.  Diverse prognostic roles of Akt isoforms, PTEN and PI3K in tumor epithelial cells and stromal compartment in non-small cell lung cancer. , 2009, Anticancer research.

[14]  C. Kolbitsch,et al.  Increased activated Akt expression in renal cell carcinomas and prognosis , 2009, Journal of cellular and molecular medicine.

[15]  Meijing Wang,et al.  Estrogen receptor beta mediates increased activation of PI3K/Akt signaling and improved myocardial function in female hearts following acute ischemia. , 2009, American journal of physiology. Regulatory, integrative and comparative physiology.

[16]  Y. Doki,et al.  The activation of Akt during preoperative chemotherapy for esophageal cancer correlates with poor prognosis. , 2008, Oncology reports.

[17]  S. Kyo,et al.  Concomitant activation of AKT with extracellular‐regulated kinase 1/2 occurs independently of PTEN or PIK3CA mutations in endometrial cancer and may be associated with favorable prognosiss , 2007, Cancer science.

[18]  M. Yasuno,et al.  PIK3CA mutation is predictive of poor survival in patients with colorectal cancer , 2007, International journal of cancer.

[19]  A. Nysted,et al.  Comparing the Prognostic Value of PTEN and Akt Expression with the Mitotic Activity Index in Adjuvant Chemotherapy-Treated Node-Negative Breast Cancer patients aged <55 years , 2007, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[20]  K. Münstedt,et al.  Prognostic value of PIK3CA and phosphorylated AKT expression in ovarian cancer , 2007, Virchows Archiv.

[21]  M. Foulkes,et al.  Prognosis of children with soft tissue sarcoma who relapse after achieving a complete response. A report from the intergroup rhabdomyosarcoma study I , 2006, Cancer.

[22]  I. H. Koumakpayi,et al.  Expression and localisation of Akt-1, Akt-2 and Akt-3 correlate with clinical outcome of prostate cancer patients , 2006, British Journal of Cancer.

[23]  N. Naka,et al.  Prognostic Significance of Activated AKT Expression in Soft-Tissue Sarcoma , 2006, Clinical Cancer Research.

[24]  R. Phimolsarnti,et al.  The outcomes and prognostic factors of patients with soft-tissue sarcoma. , 2006, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[25]  R. Guo,et al.  Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. , 2006, Lung cancer.

[26]  Yiling Lu,et al.  Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery , 2005, Nature Reviews Drug Discovery.

[27]  Neal Rosen,et al.  The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. , 2005, Cancer cell.

[28]  W. Mendenhall,et al.  Retroperitoneal soft tissue sarcoma , 2005, Cancer.

[29]  K. S. Hall,et al.  Time dependence of prognostic factors for patients with soft tissue sarcoma , 2004, Cancer.

[30]  I. Dickinson,et al.  SURGICAL MARGIN AND ITS INFLUENCE ON SURVIVAL IN SOFT TISSUE SARCOMA , 2004, ANZ journal of surgery.

[31]  M. Ballo,et al.  Prognostic factors for disease-specific survival after first relapse of soft-tissue sarcoma: analysis of 402 patients with disease relapse after initial conservative surgery and radiotherapy. , 2003, International journal of radiation oncology, biology, physics.

[32]  Jonathan J. Lewis,et al.  Histopathologic Type: An Independent Prognostic Factor in Primary Soft Tissue Sarcoma of the Extremity? , 2003, Annals of Surgical Oncology.

[33]  B. Stoica,et al.  Ceramide-induced neuronal apoptosis is associated with dephosphorylation of Akt, BAD, FKHR, GSK-3β, and induction of the mitochondrial-dependent intrinsic caspase pathway , 2003, Molecular and Cellular Neuroscience.

[34]  E. Gabrielson,et al.  High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  M. Hung,et al.  Akt activation by estrogen in estrogen receptor-negative breast cancer cells. , 2001, Cancer research.

[36]  I. Roninson,et al.  Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. , 2001, Genes & development.

[37]  Z. Lu,et al.  AKT-1, -2, and -3 are expressed in both normal and tumor tissues of the lung, breast, prostate, and colon. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  J M Woodruff,et al.  Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. , 1998, Annals of surgery.

[39]  Lewis C Cantley,et al.  PI3K: Downstream AKTion Blocks Apoptosis , 1997, Cell.

[40]  G. Rosen,et al.  High grade soft tissue sarcoma of the flexor fossae. Size rather than compartmental status determine prognosis , 1995, Cancer.

[41]  P. Gustafson.  Soft tissue sarcoma. Epidemiology and prognosis in 508 patients. , 1994, Acta orthopaedica Scandinavica. Supplementum.

[42]  T. Nakagawa,et al.  Activation of AKT in feline mammary carcinoma: a new prognostic factor for feline mammary tumours. , 2012, Veterinary journal.

[43]  D. Glass.  PI3 kinase regulation of skeletal muscle hypertrophy and atrophy. , 2010, Current topics in microbiology and immunology.

[44]  J. Freeman,et al.  Targeted therapy of human osteosarcoma with 17AAG or rapamycin: characterization of induced apoptosis and inhibition of mTOR and Akt/MAPK/Wnt pathways. , 2009, International journal of oncology.

[45]  F. Mertens,et al.  World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone , 2002 .

[46]  E. Berg,et al.  World Health Organization Classification of Tumours , 2002 .